Barclays Forecasts Strong Price Appreciation for Biogen (NASDAQ:BIIB) Stock

Biogen (NASDAQ:BIIB) had its price objective lifted by Barclays from $200.00 to $230.00 in a report issued on Wednesday, Benzinga reports. The brokerage presently has an “equal weight” rating on the biotechnology company’s stock. Barclays‘s target price would suggest a potential downside of 8.02% from the stock’s current price.

BIIB has been the topic of a number of other reports. BMO Capital Markets reaffirmed a “market perform” rating and set a $220.00 price target on shares of Biogen in a research report on Monday, October 12th. Zacks Research raised shares of Biogen from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 28th. Truist Financial upgraded shares of Biogen from a “hold” rating to a “buy” rating and increased their target price for the stock from $190.00 to $235.00 in a research report on Monday, July 13th. HC Wainwright raised their target price on shares of Biogen from $237.00 to $251.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Finally, HSBC lifted their price target on shares of Biogen from $165.00 to $175.00 and gave the company a “reduce” rating in a research report on Thursday, September 10th. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $242.96.

Biogen Price Performance

Shares of NASDAQ:BIIB traded down $2.67 on Wednesday, hitting $250.06. The company had a trading volume of 561,351 shares, compared to its average volume of 1,206,866. Biogen has a 1-year low of $138.00 and a 1-year high of $258.78. The stock has a 50 day moving average price of $225.10 and a 200 day moving average price of $200.10.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Wednesday, October 28th. The biotechnology company reported $2.62 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.63. The company had revenue of $2.80 billion during the quarter, compared to the consensus estimate of $2.63 billion. The firm’s revenue was up 10.6% compared to the same quarter last year. During the same period in the prior year, the company earned $4.81 earnings per share. Equities analysts expect that Biogen will post 12.29 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. grew its position in Biogen by 14.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 26,959 shares of the biotechnology company’s stock worth $6,122,000 after acquiring an additional 3,462 shares during the last quarter. TOWER TRUST & INVESTMENT Co boosted its position in Biogen by 6.8% during the 3rd quarter. TOWER TRUST & INVESTMENT Co now owns 3,010 shares of the biotechnology company’s stock worth $680,000 after buying an additional 192 shares during the period. D.A. Davidson & CO. grew its holdings in Biogen by 28.5% during the 3rd quarter. D.A. Davidson & CO. now owns 1,496 shares of the biotechnology company’s stock worth $338,000 after acquiring an additional 332 shares during the last quarter. North Dakota State Investment Board grew its holdings in Biogen by 3.9% during the 3rd quarter. North Dakota State Investment Board now owns 4,514 shares of the biotechnology company’s stock worth $1,020,000 after acquiring an additional 171 shares during the last quarter. Finally, Generali Asset Management SPA SGR grew its holdings in Biogen by 4.6% during the 3rd quarter. Generali Asset Management SPA SGR now owns 36,993 shares of the biotechnology company’s stock worth $8,356,000 after acquiring an additional 1,619 shares during the last quarter. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen reported adjusted earnings of $2.62 per share, exceeding the Zacks consensus estimate of $2.06 and the broader consensus cited by MarketBeat of $1.99. Revenue reached $2.804 billion, above expectations of roughly $2.63 billion and up 11% year over year. Biogen Inc. Tops Q3 Earnings and Revenue Estimates
• Positive Sentiment: Growth Portfolio revenue rose 49% to $1.26 billion, benefiting from the first full quarter of contributions from acquired Apellis products. Total product revenue increased 13%, while rare-disease revenue grew 27% to $676 million, supporting the diversification strategy beyond multiple sclerosis treatments. Biogen Q3 Revenue Rises 11% as GAAP Loss Widens
• Positive Sentiment: Management raised the lower end of its 2026 reported non-GAAP diluted EPS outlook, now guiding to $12.20–$13.00. Piper Sandler also maintained its Buy rating, reinforcing bullish sentiment around Biogen’s growth products and acquisitions. Piper Sandler Maintains Buy Rating
• Neutral Sentiment: Biogen posted a GAAP net loss of $20.6 million, or $0.14 per share, versus year-ago GAAP earnings of $466.5 million, primarily reflecting $284 million of acquired in-process research and development, upfront and milestone expenses tied largely to the RayThera acquisition. These are significant near-term charges but may support future growth.
• Negative Sentiment: GAAP earnings declined sharply from $3.17 to a loss of $0.14 per share, and the stock’s strong recent run has raised concerns that much of the expected improvement is already reflected in its valuation. Biogen also ended the quarter with approximately $7.7 billion of debt, a consideration as acquisition spending continues.

About Biogen

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.